Affitope PD03A: Phase I started

Affiris and the SYMPATH consortium began the single-blind, placebo-controlled, Austrian Phase I AFF011 trial to evaluate 4 injections of 15 and 75 µg subcutaneous Affitope PD03A plus an adjuvant every...